Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1884527 | 0.83 | GSK3B (0.50) | UHRF1PROKR1SMARCA2SMARCA4HDAC3 | |
| SCHEMBL17064644 | 0.83 | UHRF1 (0.42) | UHRF1MAPTPROKR1SMARCA2SMARCA4 | |
| SCHEMBL29740180 | 0.83 | GSK3B (0.50) | UHRF1PROKR1SMARCA2SMARCA4HDAC3 | |
| SCHEMBL29740179 | 0.83 | GSK3B (0.50) | UHRF1PROKR1SMARCA2SMARCA4HDAC3 | |
| SCHEMBL12672263 | 0.83 | UHRF1 (0.42) | UHRF1KMT2AMAPTPROKR1SMARCA2 | |
| Hydrochloric Acid SCHEMBL1924951 | 0.81 | UHRF1 (0.41) | UHRF1KMT2AMAPTPROKR1SMARCA2 | |
| Bromide SCHEMBL14676183 | 0.81 | GSK3B (0.48) | UHRF1PROKR1SMARCA2SMARCA4HDAC3 | |
| Hydrochloric Acid SCHEMBL14676437 | 0.81 | GSK3B (0.48) | UHRF1PROKR1SMARCA2SMARCA4HDAC3 | |
| Bromide SCHEMBL23407677 | 0.80 | GSK3B (0.47) | UHRF1PROKR1SMARCA2SMARCA4HDAC3 | |
| SCHEMBL11625130 | 0.80 | ALDH1A1 (0.50) | MEN1KMT2ASMN1; SMN2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106277159-A | A kind of methylene blue and the processing method of Congo red organic pollution | 渤海大学 | 2017-01-04 | — | — | CN | claimed |
| US-20230295114-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-09-21 | — | — | US | disclosed |
| CN-112569895-B | Preparation method of organic anionic dye adsorbent with high adsorption capacity, product and application thereof | 徐州瑞鑫新材料研究院有限公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-113908802-A | Copper-based compound for adsorbing organic anionic dye | 天津理工大学 | 2022-01-11 | — | — | CN | disclosed |
| CN-106277159-A | A kind of methylene blue and the processing method of Congo red organic pollution | 渤海大学 | 2017-01-04 | — | — | CN | disclosed |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8518945-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2013-08-27 | — | — | US | disclosed |
| EP-2593426-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F.HOFFMANN-LA ROCHE AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| WO-2012007365-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | disclosed |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | HENDRICKS ROBERT THAN | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295114-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | UHRF1 3714/4885ATM 304/4885MEN1 1926/4885 |
| US-20110230462-A1 | Pyrrolopyrazine Kinase Inhibitors | SYK, ZAP70, BTK | UHRF1 1303/4885ATM 669/4885MEN1 4109/4885 |
| US-20140031334-A1 | DERIVATIVES OF 4-PIPERAZIN-1-YL-4-BENZO[B]THIOPHENE SUITABLE FOR THE TREATMENT OF CNS DISORDERS | GRIN2C, GRIN2B, PMP22 | UHRF1 2629/4885ATM 2717/4885MEN1 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.